Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...

Results showed tarlatamab demonstrated statistically significant and clinically meaningful improvement in overall survival vs standard of care therapy. Topline data were announced from a phase 3 ...

Purdue University scientists have identified the Supinoxin molecule as a possible new therapy for small cell lung cancer.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

YAP, a protein known to help cancer cells survive treatment, behaves very differently in cell culture models depending on how they are grown in the lab, highlighting the importance of mimicking tumour ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically significant and clinically meaningful improvement in overall survival compared ...